NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that it will present a company overview at the upcoming Biotech Showcase conference.
SAN FRANCISCO, Jan. 3, 2022 /PRNewswire/ -- NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that it will present a company overview at the upcoming Biotech Showcase conference. This pre-recorded presentation will be available during Biotech Showcase to all registered attendees. Event: Biotech Showcase The presentation will highlight QSant™, the first entirely non-invasive test for early detection of risk of kidney transplant rejection, without requiring an invasive kidney biopsy. QSant is a test for both adult and pediatric transplant recipients. QSant can deliver accurate quantification of kidney transplant rejection risk from a non-timed urine sample that can be collected in a patient’s home. The presentation will review clinical studies and real-world experience about the utility of this urine test. QSant is also being offered to patients through the AQUA registry . QSant™ is fully reimbursed by Medicare when appropriately ordered by a healthcare professional. Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. As in years past, qualified investors and members of the press are entitled to complimentary registration. About Chronic Kidney Disease and Transplantation About QSant™ When ordered by a treating physician, QSant collection kit is shipped to the patient’s home. A single urine sample is collected and shipped back directly to the NephroSant lab for analysis. NephroSant’s proprietary algorithm generates a personalized Q-Score™, which quantifies risk of rejection personalized to a particular patient. This score is delivered directly to the physician to inform and assist decision making for post-transplant care. During development, more than 1,000 patient samples were analyzed using QSant and the clinical and analytical validation of the test published in the journal, Science Translational Medicine¹. QSant has been studied through NephroSant’s Early Access Program (EAP) conducted within a select group of 11 transplant centers in the US. Feedback from physicians and patients surveyed in the EAP supports QSant’s accuracy for rejection detection, straight forward use and convenient in-home collection. About NephroSant™ ¹ Yang , Sarwal et al., Science Translational Medicine, 2020 Contacts Media, Patients and Providers: View original content:https://www.prnewswire.com/news-releases/nephrosant-features-qsant-the-first-urine-test-for-kidney-transplant-rejection-at-biotech-showcase-digital-2022-301452570.html SOURCE NephroSant |